October 08 2025
NRG Oncology seeks to fill the position of Chair, NRG Oncology Medical Oncology Committee
Application Deadline: October 31, 2025 Read more
September 30 2025
NRG Oncology Trial Analysis Shows Improvement in Survival Outcomes for Glioblastoma Patients Receiving Proton Therapy, Trial Moves to Phase III
Previously, results from the photon cohort of NRG-BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not demonstrate improvement in overall survival (OS) for patients with newly diagnosed glioblastoma (GBM). The recent analysis of the proton cohort revealed improved survival for patients receiving proton therapy at 75 Gy. Because this data met the pre-defined survival improvement threshold, they could be used to design and conduct a definitive phase III randomized trial. These results were recently reported at the American Society for Radiation Oncology Annual Meeting in San Francisco, California. Read more
August 28 2025
NRG Oncology seeks to fill the position of Chair of the NRG Oncology Translational Science Committee.
Application Deadline: September 29, 2025 Read more
August 25 2025
NRG Oncology seeks to fill the position of translational science Vice Chair, NRG Oncology Lung Cancer Committee
Application Deadline: September 29, 2025 Read more
August 25 2025
NRG Oncology seeks to fill the position of translational science Vice Chair, NRG Oncology Developmental Therapeutics Committee
Application Deadline: September 29, 2025 Read more
November 12 2024
Advocate Angle: "Life's a journey - travel well"
Written by Mark Harris, an NRG Oncology Patient Advocate Committee Member Read more
November 12 2024
Advocate Angle: Improving the Cancer Clinical Trial Matching Ecosystem
Written by Wenora Johnson, Patient/Research Advocate (Fight CRC) & NRG Oncology Patient Advocate Committee Member Read more
November 12 2024
NRG-GU011 (“NRG PROMETHEAN”): stereotactic radiotherapy with or without relugolix for PET-recurrent oligometastatic prostate cancer
Written by Bridget Koontz, MD FASTRO, AdventHealth Cancer Institute, National PI for NRG-GU011 Read more
November 12 2024
Moving anti-HER2 therapy into the peri-operative setting for locally advanced esophagogastric cancer
Written by Geoffrey Y. Ku, MD; Gastrointestinal Oncology Service, Dept of Medicine, Memorial Sloan Kettering Cancer Center Read more
October 10 2024
Advocate Angle: An Interview with Laurel Pracht: Making Strides to Fund the Future in Ovarian Cancer Research
Our NRG Communications team interviewed Laurel to discuss the fundraising efforts and her passions surrounding cancer research and health equities. Read more
October 10 2024
Navigating the Vast World of Clinical Research Following an Adolescent Young Adult (AYA) Cancer Diagnosis
Advocate Angle by Jade Gibson an NRG Oncology Patient Advocate Read more
September 12 2024
Adding Stereotactic Radiation Therapy to Immune Therapy for Patients with Advanced Renal Cell Cancer (NRG-GU012, The “SAMURAI” Study)
NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) Read more
September 12 2024
Comparing Stereotactic Radiosurgery to Fractionated Stereotactic Radiosurgery for Patients with Cancer that has Spread to the Brain (NRG-BN013)
NRG-BN013: Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases Read more
September 12 2024
My Hereditary Cancer Journey: Looking Back, Look Forward
Article by Diane Rose an NRG Oncology Patient Advocate Read more
January 17 2024
A Message from the Chairs of NRG Oncology’s Research Strategy Committee
2023: The Year in Review Read more